FBX

ethyl N-[2-azanyl-4-[(4-fluorophenyl)methylamino]phenyl]carbamate

Find entries where: FBX

is present as a standalone ligand in 3 entries

Find related ligands:

Chemical Component Summary
Name	ethyl N-[2-azanyl-4-[(4-fluorophenyl)methylamino]phenyl]carbamate
Synonyms	Retigabine; Ezogabine
Identifiers	ethyl ~{N}-[2-azanyl-4-[(4-fluorophenyl)methylamino]phenyl]carbamate
Formula	C₁₆ H₁₈ F N₃ O₂
Molecular Weight	303.331
Type	NON-POLYMER
Isomeric SMILES	CCOC(=O)Nc1ccc(cc1N)NCc2ccc(cc2)F
InChI	InChI=1S/C16H18FN3O2/c1-2-22-16(21)20-15-8-7-13(9-14(15)18)19-10-11-3-5-12(17)6-4-11/h3-9,19H,2,10,18H2,1H3,(H,20,21)
InChIKey	PCOBBVZJEWWZFR-UHFFFAOYSA-N

Chemical Details
Formal Charge	0
Atom Count	40
Chiral Atom Count	0
Bond Count	41
Aromatic Bond Count	12

Drug Info: DrugBank

DrugBank ID	DB04953
Name	Ezogabine
Groups	investigational approved
Description	Ezogabine (D23129) is a close structural analog of the centrally acting analgesic flupitrine. It is a neuronal potassium channel opener being developed as a first-in-class antiepileptic drug (AED) and is currently being studied in Phase 3 trials as an adjunctive treatment for partial-onset seizures in adult patients with refractory epilepsy. FDA approved in June 10, 2011 under the name of ezogabine.
Synonyms	N-(2-Amino-4-(4-fluorobenzylamino)phenyl)carbamic acid ethyl ester Retigabine Ezogabine Retigabina EZG RTG ethyl {2-amino-4-[(4-fluorobenzyl)amino]phenyl}carbamate Ethyl 2-amino-4-((p-fluorobenzyl)amino)carbanilate N-(2-Amino-4-(4-fluorobenzylamino)-phenyl) carbamic acid ethyl ester
Brand Names	Potiga Trobalt
Indication	Adjuvant treatment of partial-onset seizures.
Categories	Acids, Acyclic Amines Aniline Compounds Anticonvulsants Central Nervous System Agents Central Nervous System Depressants Diamines Drugs that are Mainly Renally Excreted Membrane Transport Modulators Nervous System Polyamines Potassium Channel Opener Potential QTc-Prolonging Agents QTc Prolonging Agents UGT1A1 Substrates UGT1A3 substrates UGT1A4 substrates UGT1A9 Substrates
ATC-Code	N03AX21
CAS number	150812-12-7

Drug Targets

Name	Target Sequence	Pharmacological Action	Actions
Potassium voltage-gated channel subfamily KQT member 2	MVQKSRNGGVYPGPSGEKKLKVGFVGLDPGAPDSTRDGALLIAGSEAPKR...	unknown
Potassium voltage-gated channel subfamily KQT member 3	MGLKARRAAGAAGGGGDGGGGGGGAANPAGGDAAAAGDEERKVGLAPGDV...	unknown
Potassium voltage-gated channel subfamily KQT member 4	MAEAPPRRLGLGPPPGDAPRAELVALTAVQSEQGEAGGGGSPRRLGLLGS...	unknown
Potassium voltage-gated channel subfamily KQT member 5	MPRHHAGGEEGGAAGLWVKSGAAAAAAGGGRLGSGMKDVESGRGRVLLNS...	unknown
UDP-glucuronosyltransferase 1-1	MAVESQGGRPLVLGLLLCVLGPVVSHAGKILLIPVDGSHWLSMLGAIQQL...	unknown	substrate
UDP-glucuronosyltransferase 1-3	MATGLQVPLPWLATGLLLLLSVQPWAESGKVLVVPIDGSHWLSMREVLRE...	unknown	substrate
UDP-glucuronosyltransferase 1-4	MARGLQVPLPRLATGLLLLLSVQPWAESGKVLVVPTDGSPWLSMREALRE...	unknown	substrate
UDP-glucuronosyltransferase 1-9	MACTGWTSPLPLCVCLLLTCGFAEAGKLLVVPMDGSHWFTMRSVVEKLIL...	unknown	substrate
Arylamine N-acetyltransferase 2	MDIEAYFERIGYKNSRNKLDLETLTDILEHQIRAVPFENLNMHCGQAMEL...	unknown	substrate
View More

Drug Info/Drug Targets: DrugBank 3.0: a comprehensive resource for 'omics' research on drugs. Knox C, Law V, Jewison T, Liu P, Ly S, Frolkis A, Pon A, Banco K, Mak C, Neveu V, Djoumbou Y, Eisner R, Guo AC, Wishart DS. Nucleic Acids Res. 2011 Jan; 39 (Database issue):D1035-41. | PMID:21059682